Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Bio-Rad Laboratories, Inc. BIO.B

Healthcare  —  Medical Devices
365.08 0.00 0.00% as of 24 Sep
Market cap
$10.3B
P/E
43.8×
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Bio-Rad Laboratories, Inc. (BIO.B) Business Profile

Updated before January 2025

Company Overview

Bio-Rad Laboratories, Inc. (BIO.B) is a global leader in the development and manufacturing of innovative products for the life sciences research and clinical diagnostics markets. Founded in 1952 by David and Alice Schwartz, the company is headquartered in Hercules, California, USA. Over the decades, Bio-Rad has grown into a multinational corporation with a presence in over 35 countries, employing thousands of professionals worldwide. The company is led by Norman Schwartz, who serves as Chairman of the Board, President, and Chief Executive Officer. Under his leadership, Bio-Rad has continued to expand its product portfolio and strengthen its position in the global market.

Core Business Segments

Bio-Rad operates through two primary business segments: Life Science and Clinical Diagnostics. Each segment offers a wide range of products and services tailored to meet the needs of researchers, healthcare providers, and diagnostic laboratories.

Life Science Segment

The Life Science segment focuses on providing tools and technologies for biological research and drug discovery. Key product categories include:

  • Gene Expression and Genomics: Instruments and reagents for PCR, qPCR, and next-generation sequencing (NGS) workflows.
  • Proteomics: Products for protein analysis, including electrophoresis systems, western blotting reagents, and imaging systems.
  • Cell Biology: Flow cytometry instruments, cell sorting systems, and reagents for cell analysis.
  • Biopharmaceutical Development: Chromatography systems and consumables for protein purification and drug development.

Clinical Diagnostics Segment

The Clinical Diagnostics segment provides products and systems for disease diagnosis and monitoring. Key offerings include:

  • Immunoassays: Automated analyzers and reagents for detecting infectious diseases, autoimmune disorders, and cancer biomarkers.
  • Diabetes Monitoring: HbA1c testing systems for diabetes management.
  • Blood Typing and Transfusion Medicine: Instruments and reagents for blood group typing and compatibility testing.
  • Quality Control Systems: Tools for ensuring the accuracy and reliability of diagnostic test results.

Business Model

Bio-Rad’s business model is centered on innovation, quality, and customer support. The company integrates its products and services to provide comprehensive solutions for its customers. Revenue is generated through the sale of instruments, consumables, and services. Consumables, such as reagents and test kits, provide a recurring revenue stream, while service contracts and software subscriptions add additional stability to the company’s financial performance. Bio-Rad also invests heavily in research and development (R&D) to maintain its competitive edge and address emerging market needs.

Strategic Direction

Bio-Rad is committed to driving growth through innovation, operational excellence, and strategic acquisitions. Key strategic priorities include:

  • Expanding Product Portfolio: Developing new products and enhancing existing ones to address unmet needs in life sciences and diagnostics.
  • Sustainability Goals: Implementing environmentally friendly practices in manufacturing and product design to reduce the company’s carbon footprint.
  • Geographic Expansion: Increasing market penetration in emerging economies to capitalize on growing demand for advanced diagnostic and research tools.
  • Digital Transformation: Leveraging data analytics and artificial intelligence (AI) to improve product performance and customer experience.

Competitive Landscape

Bio-Rad operates in highly competitive markets, facing competition from both established players and emerging companies. Key competitors include:

  • Life Sciences: Thermo Fisher Scientific, Agilent Technologies, and Illumina.
  • Clinical Diagnostics: Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers.

Despite the competition, Bio-Rad differentiates itself through its strong brand reputation, innovative product offerings, and customer-centric approach.

Risk Factors

Like any business, Bio-Rad faces several risks that could impact its performance. Key risk factors include:

  • Market Dependence: Reliance on the life sciences and diagnostics markets, which are subject to fluctuations in research funding and healthcare spending.
  • Supply Chain Disruptions: Potential delays or shortages in raw materials and components due to global supply chain challenges.
  • Regulatory Compliance: The need to comply with stringent regulations in multiple jurisdictions, which can increase operational complexity and costs.
  • Currency Exchange Rates: Exposure to foreign currency fluctuations due to its global operations.

Recent Developments

Bio-Rad has recently introduced several innovative products and initiatives to strengthen its market position. Notable developments include:

  • Launch of New PCR Systems: Advanced instruments designed to improve the speed and accuracy of genetic analysis.
  • Acquisition of Emerging Companies: Strategic acquisitions to enhance its capabilities in areas such as digital PCR and single-cell analysis.
  • COVID-19 Response: Development of diagnostic tests and research tools to support the global fight against the pandemic.

Additionally, Bio-Rad has been actively investing in digital technologies to improve its product offerings and operational efficiency.

Investment Considerations

Investors considering Bio-Rad should weigh the following strengths and risks:

Strengths

  • Strong brand reputation and market leadership.
  • Diversified product portfolio with recurring revenue streams.
  • Robust R&D capabilities and commitment to innovation.
  • Global presence and expanding footprint in emerging markets.

Risks

  • Exposure to market fluctuations and economic downturns.
  • Dependence on regulatory approvals for new products.
  • Competitive pressures from established and emerging players.
  • Potential impact of geopolitical tensions on global operations.

Conclusion

Bio-Rad Laboratories, Inc. is a well-established leader in the life sciences and clinical diagnostics markets. With a strong focus on innovation, sustainability, and customer satisfaction, the company is well-positioned for future growth. While it faces challenges such as market competition and regulatory complexities, its diversified product portfolio and strategic initiatives provide a solid foundation for long-term success.